4.6 Letter

Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all-trans retinoic acid and arsenic trioxide sensitivity

Related references

Note: Only part of the references are listed.
Review Oncology

Current views on the genetic landscape and management of variant acute promyelocytic leukemia

Xiang Zhang et al.

Summary: Acute promyelocytic leukemia (APL) consists of typical APL and variant APL, with the latter showing distinct features and challenges in recognition, diagnosis, and treatment. Genetic studies have revealed a great heterogeneity in the genetics of variant APL, with different rearrangements other than RARA/RARB/RARG being able to drive the disease. Treatment for variant APL often involves combined chemotherapy instead of differentiation induction therapy.

BIOMARKER RESEARCH (2021)

Review Oncology

Classic and Variants APLs, as Viewed from a Therapy Response

Marie-Claude Geoffroy et al.

CANCERS (2020)

Article Biochemistry & Molecular Biology

NAB2 represses transcription by interacting with the CHD4 subunit of the nucleosome remodeling and deacetylase (NuRD) complex

Rajini Srinivasan et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2006)

Article Multidisciplinary Sciences

All-trans retinoic acid/AS2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia

ZX Shen et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)